Effect of systemic enzymotherapy on Cesarean section scar healing

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10329308" target="_blank" >RIV/00064165:_____/16:10329308 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/16:10329308

Výsledek na webu

<a href="http://www.prolekare.cz/linkout/59622" target="_blank" >http://www.prolekare.cz/linkout/59622</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of systemic enzymotherapy on Cesarean section scar healing

Popis výsledku v původním jazyce

Objectives: The aim of our study was to monitor changes in the healing of Caesarean section scars in patients using systemic enzymotherapy in comparison with patients not treated with systemic enzymotherapy (Wobenzym). Methods: A prospective cohort study was conducted in 60 primiparous women delivered by CS. We compared the following outcomes: scar thickness after the Caesarean section, dehiscence risk coefficient (DRC), severity of the Caesarean section scar defect, uterine cavity dilation, post-operative pain, C-reactive protein level and febrility. Results: The scar thickness 6 weeks after CS was significantly greater in the group of patients taking Wobenzym (7.1+-0.9 mm; mean +- SD) than in the patients without Wobenzym (5.3+-0.7 mm) (p = 0.01). Severe Caesarean section scar defects were observed in 1/30 (3.3%) Wobenzym users and in 5/30 (16.7%) patients who did not use Wobenzym, with no statistically significant difference (p = 0.195). Conclusion: Despite the percentage of patients with a severe CS scar defect being apparently lower in the group treated with Wobenzym, the difference did not reach statistical significance due to the small size of the study population.

Název v anglickém jazyce

Effect of systemic enzymotherapy on Cesarean section scar healing

Popis výsledku anglicky

Objectives: The aim of our study was to monitor changes in the healing of Caesarean section scars in patients using systemic enzymotherapy in comparison with patients not treated with systemic enzymotherapy (Wobenzym). Methods: A prospective cohort study was conducted in 60 primiparous women delivered by CS. We compared the following outcomes: scar thickness after the Caesarean section, dehiscence risk coefficient (DRC), severity of the Caesarean section scar defect, uterine cavity dilation, post-operative pain, C-reactive protein level and febrility. Results: The scar thickness 6 weeks after CS was significantly greater in the group of patients taking Wobenzym (7.1+-0.9 mm; mean +- SD) than in the patients without Wobenzym (5.3+-0.7 mm) (p = 0.01). Severe Caesarean section scar defects were observed in 1/30 (3.3%) Wobenzym users and in 5/30 (16.7%) patients who did not use Wobenzym, with no statistically significant difference (p = 0.195). Conclusion: Despite the percentage of patients with a severe CS scar defect being apparently lower in the group treated with Wobenzym, the difference did not reach statistical significance due to the small size of the study population.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FK - Gynekologie a porodnictví

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Česká gynekologie

ISSN

1210-7832

e-ISSN

—

Svazek periodika

81

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

202-207

Kód UT WoS článku

000389361500007

EID výsledku v databázi Scopus

2-s2.0-85002626942